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In this chapter, we describe and reflect on some selected 
accomplishments made in cancer epidemiology during 
the last 200 years in Norway. We have a special em-
phasis on the last 25 years i.e. during NOFE’s lifetime. 
We have tried to do this in a global context. Norwe-
gian epidemiologists founded NOFE in 1990. At that 
time, the list of accomplishments in cancer epidemio-
logy was not so extensive. Researchers in cancer epi-
demiology have made a lot of progress during the last 
25 years. Worldwide, epidemiologists and data from 
Norway have played important roles and increased this 
research knowledge. It is essential that this research 
continue. Deaths from cancer will be the most com-
mon cause in Norway in the near future. 
 Tobacco use, particularly cigarette smoking should 
still be the main cancer control priority. We have 
chosen the relationship between smoking and cancer to 
picture the change that has been happening. In the 
1990s results from single Norwegian cohort studies 
were published. Today, it is more common that data 
from the same cohorts are included in larger European, 
international and consortium collaborations. Results 
from Norwegian cohort studies have contributed to 
knowledge necessary for cancer prevention, as inde-
pendent studies and in collaborations with researchers 
from other countries and fields in science. This chapter 
will introduce young researchers to some of the studies 
that are available for continued cancer research. We 
must apologize to those who played key roles in dis-




FREQUENT CANCERS GLOBALLY AND IN 
NORWAY TODAY 
 
Globally, as pointed out in the World Cancer Report 
from 2014, cancer is a major cause of morbidity and 
mortality. The approximately 14 million new cases and 
8 million cancer related deaths, annually, are affecting 
populations in all countries and regions. In 2012, the 
three most common incident cancers were breast 
(25.2% of the total), colorectal (9.2%) and lung (8.7%) 
cancer among women and lung (16.7% of the total), 
prostate (15.0%) and colorectal (10.0%) cancer among 
men (1). These cancers were also the most frequent in 
Norway (2). 
CANCER EPIDEMIOLOGY IN NORWAY 
1815-1990 
 
The first century of this period was totally dominated 
by infectious diseases as major causes of deaths. In 
Norway, tuberculosis was the main killer among young 
people. The only source of information on cancer was 
the death statistics. Until the 1930s, cancer was not a 
major cause of death. In the years before the second 
world war, the tuberculosis epidemic decreased rapidly 
and deaths from cancer increased, especially among 
the elderly. As in other European countries, the rapid 
increase in lung cancer among men became a particu-
lar concern. In Norway, from 1930 until 1950, Profes-
sor Kreyberg did an important work by establishing a 
systematic and reliable way to diagnose lung cancer. 
He documented the lung cancer epidemic (3), estab-
lished different histo-pathological subtypes (4) and 
found differences in lung cancer incidence depending 
on urban and rural residence (5). It was not until the 
beginning of the fifties that researchers understood that 
the increase in lung cancer incidence was related to 
smoking. This was shown for Scandinavia in a 
comparative study of lung cancer in Finland and 
Norway (6). 
 The early work in cancer epidemiology depended 
on The Norwegian Radium Hospital (DNR), which 
opened in 1932. This was also the start of clinical 
research related to survival of breast cancer. The 25th 
anniversary describes that from 1932 to 1951, one out 
of four cancer cases was inoperable with a five-year 
survival of 8%. 
 Two national cancer associations, founded in 1938 
and in 1950, were important for cancer research in the 
postwar era. The first collected money for research 
with a particular focus on diet and risk of cancer. The 
latter collected money for basic cancer research 
conducted at DNR. In 1988, these two important 
organizations merged and is today the Norwegian 
Cancer Society (https://kreftforeningen.no/). 
 The Norwegian Government decided to establish 
the Cancer Registry of Norway, Institute of Population-
based Cancer Research in 1951. For cancer epidemio-
logy, this resolution is the most important from the 
20th century. The Registry is one of the oldest national 
cancer registries in the world. The Registry collects 
data based on compulsory notification of all newly 
diagnosed cancers from clinicians, pathologists and 
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Figure 1.  Time trends in age-standardised incidence rates (world) in Norway for selected cancers (semi log-scale), males 
(a) and females (b) 1953-2012 (2). 
 
 
death certificates. The Cancer Registry has published 
descriptive statistics like annual incidence figures, 
periodically survival reports, and geographic analyses 
of incidence. In addition, several important classic 
descriptive studies were published on malignant mela-
noma and other sites of cancer (7). Figures 1a and 1b 
show the cancer register data from 1953-2012 for both 
genders (2). 
 For more than thirty years, the Cancer Registry was 
the central institution for cancer epidemiology. Besides 
cancer statistics, the staff conducted several analytical 
projects, mainly within occupational cancer research. 
The projects were record-linkage studies between 
roosters of employed people and the cancer files. The 
first report was on the carcinogenic effect of nickel 
exposures (8) followed by many others (9). Through 
co-operation with the National Institute of Health, US, 
the first large collection of questionnaire information, 
the Migrant study, took place in Norway, England and 
the US. This study was also part of the first PhD at the 
Cancer Registry with its well-known finding of a 
protective effect of vitamin A on lung cancer risk (10). 
The Migrant study was originally a study of bronchitis, 
but later developed into a prospective cohort study of 
smoking and cancer (11). 
 Outside the Cancer Registry, one of the first large 
epidemiological studies was a Scandinavian population 
based case-control study on oral contraception and 
breast cancer in young women (12). During the late 
1980s, epidemiologists realized the need for a change 
from case-control to cohort studies. The implemen-
tation of the first large multicenter studies started, like 
the European Prospective Investigation into Nutrition 
and Cancer (EPIC) (13). As part of this trend, the 
Norwegian Women and Cancer study (NOWAC or 
Kvinner og Kreft, http://site.uit.no/nowac) started en-
rollment in 1991, and became seven years later a part 
of EPIC (http://epic.iarc.fr/). 
 Another source of prospective data is the informa-
tion collected as part of the national screening programs 
for cardiovascular diseases. Today the Cohort of Nor-
way (CONOR) comprises ten of these cohorts (14). 
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The health surveys covered both physical examina-
tions, questionnaire data and blood samples. The latter 
forms today the Biobank Norway, described in another 
chapter. The JANUS biobank is another large popu-
lation based biobank with blood samples from 317,000 
Norwegians. Only cancer researchers may use this 
biobank. JANUS is unique regarding size and number 
of cancer cases. There were 65,000 donors with a 
cancer diagnosis, as of December 31, 2012 (http:// 
kreftregisteret.no/). The above-described collections of 
questionnaire information, measurements and biobanks 
have led to numerous Ph.D. theses and a broad scope 




Cancer screening aims to reduce cancer specific mor-
tality by prevention or early detection and treatment of 
invasive disease. In Norway screening programs for 
breast- and cervical cancer are implemented, while 
countries in Europe also recommend screening for 
colorectal cancer. Public health recommendations are 
based on the overall estimates of risk and benefit for 
the population. Lately, a lot of emphasis has been 
about the risks and benefits for the “average” person 
undertaking a screening examination. 
 Epidemiological studies from Norway have contri-
buted to the controversial and passionate debate about 
mammography screening. Different research groups 
have published results based on data from the Nor-
wegian Breast Cancer Screening Program (NBCSP, 
Figure 2) (15-17). An expert group, appointed by the 
Research Council of Norway, have recently evaluated 
these studies. The overall conclusion was that reduction 
in breast cancer mortality attributable to the implemen-
tation of the NBCSP is in the range of 20-30% for 
women aged 50-79 years, compared to a situation with 
no screening program (18). This is in agreement with 
the conclusion by the IARC expert group (19). 
 The NORCCAP study has investigated the benefits 
and costs of colorectal cancer screening in Norway. A 
recent publication from this group showed a signifi-
cant 20% reduction in colorectal cancer incidence in a 
randomized trial with flexible sigmoidoscopy screen-
ing (20). 
 
SMOKING AND RISK OF CANCER 
 
Although the prevalence of daily smoking has been 
quite different for Norwegian men and women during 
the past sixty years, lung cancer has become the most 
common cancer killer for both (Figure 3) (21). Resear-
chers identified lung cancer as the first of seventeen 
cancers that was causally related to smoking (22,23). 
Studies from Norway, where today the majority of the 
middle-aged residents are ever (either former or 
current) smokers, have provided results helping to es-
tablish these relationships from as early as 1981 (11). 
  




Figure 3.  Smoking is the single most important cause of 
preventable cancer and cancer death. 
 
 
 In the now renowned Tromsø Studies, the first 
follow-up study was a cancer study revealing a posi-
tive association between smoking and risk of severe 
cervical dysplasia/cancer (24). Many years later, data 
from this study was included together with those from 
22 other epidemiological studies finding an increased 
risk of cervical cancer of the same magnitude for 
current compared with never smokers as in the Tromsø 
study (25). More recently, an EPIC publication con-
firmed this association also in the context of different 
HPV infections (26). In 1996, results from a cohort of 
26,000 Norwegians showed an increased risk of cancer 
of the cervix, pancreas, urinary bladder and cancers of 
the upper digestive and respiratory tract. (27). In 2004, 
IARC listed the following cancers i.e. oral cavity, 
oropharynx, nasopharynx, esophagus stomach, liver, 
pancreas, nasal cavity and sinuses, larynx, uterine cer-
vix, kidney, lower urinary tract and myeloid leukemia 
to be smoking related cancers (28). 
 In 2008, results from the Swedish-Norwegian 
Women and Lifestyle Cohort found that smokers had 
an increased risk of mucinous ovarian cancer com-
pared with never smokers (29). Results from EPIC (30) 
and from an international collaboration study (31) 
confirmed this. All three studies had individual data 
from the NOWAC cohort included. A similar example, 
where data from Norway have contributed, conveys to 
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 the smoking related increase of colorectal cancer. 
Female smokers had an increased risk of CRC com-
pared with never smokers in the NOWAC cohort (32). 
The EPIC study found this association later for both 
genders (33). The Monograph from IARC published in 
2012 and the US Surgeon General report from 2014 
both list colorectal and mucinous ovarian cancer as 
causally related to smoking (22,23). Recently, results 
from a cohort including health survey data from more 
than 600,000 Norwegians suggested that the increased 
risk of colon, but not rectal cancer, may be greater in 
women than in men (34,35). 
 Collaborative efforts, including many participants 
and cancer cases, have power to show associations that 
single studies may not show, even if there is a real 
association. On the other hand, a huge sample size of-
ten means less detailed information. An example of a 
study that may have pointed us in the wrong direction, 
is the study on alcohol consumption and smoking and 
risk of breast cancer (36). This study included close to 
60,000 breast cancer cases from 53 epidemiological 
studies. It found that alcohol consumption was to 
blame for 4% of the breast cancer cases, but that 
smoking did not increase breast cancer risk. In contrast 
to this, results from the NOWAC study updated with 
cancer cases until 2010, found that 9% of new breast 
cancer cases, i.e. one in eleven cases of the most 
common female cancer, could have been avoided if the 
women did not smoke (37). 
 The two expert reports described earlier, conclude 
that smoking may possibly increase breast cancer risk, 
but that there is not sufficient evidence to infer a 
causal relationship (22,23). These reports included 
results from the Norwegian-Swedish cohort, finding an 
increased risk of breast cancer for women who started 
to smoke as teenagers (38). Unfortunately, the results 
from two large cohort studies, including close to 7,000 
and 10,000 breast cancer cases, supporting a positive 
relationship between smoking and breast cancer, were 
published too late to be included in these evaluations. 
The first study included around 300,000 women from 
the Norwegian Health Screening Surveys (39) and the 
latter 300,000 women from EPIC (40). Results from 
the Breast and Prostate Cohort Consortium, examining 
gene-environment interactions in around 7,000 breast 
cancer cases could not convincingly explain if 
smoking is causally associated with breast cancer (41). 
Researchers in Norway have several opportunitis to 




GENE-ENVIRONEMENT STUDIES IN CANCER 
RESEARCH 
 
The description of the genome in the years around 
2000 resulted in an impressive optimism for the poten-
tial of identification of single nucleotide polymorph-
isms (SNPs) resulting in an increased risk for cancer. 
In the first few years after, a wave of positive results 
appeared when it was possible to do genome wide 
analyses, GWAS. It became relatively soon obvious; 
that most of these were false positive results due to 
lack of adequate handling of multiple testing. The 
introduction of correction for false discovery rate and 
other techniques soon changed the picture. At the same 
time, research groups built larger and larger consor-
tiums to perform huge pooled analyses. Norwegian 
cohorts have participated mainly by delivering DNA to 
the collaborating centers. 
 The lung cancer consortium with thousands of cases 
and controls is one example of a huge research effort. 
Only one SNP displayed an increase in risk of lung 
cancer, which was approximately 80%. Confronted 
with the risk increase of hundreds of percent for 
smoking this finding has little practical value (43). In 
the combined GWAS analysis of more than 60,000 
breast cancer cases and the same number of controls, 
the results revealed 15 new susceptibility loci. How-
ever, these loci explained only about 2% of the varia-
tion in breast cancer risk (44). In a review, evaluating 
the GWAS results related to cancer, the conclusion 
was negative and a bit discouraging. The general 




HORMONES, BREAST CANCER AND 
MAMMOGRAPHIC DENSITIES 
 
NOWAC was the first nationally representative cohort 
study designed to examine cancer as outcome. Initi-
ally, NOWAC had a special focus on oral contracep-
tive use and risk of breast cancer, which at that time 
was a controversial topic (46). Today, both current 
OC-use and current postmenopausal hormone use are 
established risk factors for breast cancer. Studies from 
Norway have contributed to this knowledge (47-50). 
Norwegian scientists continue to raise new questions 
in this area: How is breast cancer risk among users of 
both hormonal medications (51)? Is there an antago-
nistic effect for OC-use and alcohol consumption on 
breast cancer risk (52)? Is it possible to explore the 
etiology of breast cancer through gene expression pro-
files from peripheral blood (53,54)? Epidemiologists 
have shown that menopausal hormone use also contri-
butes to the breast cancer incidence trends in Norway 
(55,56). Researchers have used mammographic densi-
ties, one of the strongest risk factors for breast cancer, 
as surrogate endpoints for breast cancer in an effort to 
understand the association between genes, endogenous 




OBESITY AND RISK OF CANCER 
 
Assuming causality, obesity, or excess weight as 
measured by body mass index (BMI), could explain 
41% of uterine, and 10% or more of kidney, liver, gall 
bladder and colon cancers (62). Several Norwegian 
studies have shown that BMI is an important predictor 
of cancer risk and cancer deaths. In a huge record 
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linkage study that measured height and weight of two 
million Norwegian men and women from 1963 to 
2001, obesity was associated with a modest increase in 
risk of prostate (63) and an increased risk of colon 
cancer in men, and of gallbladder cancer in women 
(64). Obesity suggestively increased the risk of death 
from colon cancer in a cohort study where participants 
were aged 14-19 years at enrollment (65). In a recent 
cohort study, the authors observed that women had an 
increased risk of middle age death from cancer other 
than lung and breast cancer (66). 
 
 
PHYSICAL ACTIVITY AND RISK OF CANCER 
 
All Norwegian cohort studies have collected informa-
tion on physical activity measured as activity during 
leisure and work time, or using different scales. The 
Three County study found a protective effect of physi-
cal activity for prostate (67), colon (68) and breast (69) 
cancer. A recent study from NOWAC (70) did not 
confirm the latter association. 
 
 
ALCOHOL CONSUMPTION AND INFECTIONS 
AND RISK OF CANCER 
 
As summarized in the World Cancer Report, alcohol 
consumption causes cancer of the mouth, pharynx, 
larynx, esophagus, liver, colorectum and female breast. 
Globally, infections with Helicobacter pylori, hepatitis 
B and C viruses, and human papillomaviruses (HPV) 
are responsible for a huge (1.9 million cancer cases) 
number of gastric, liver and cervical cancer, respec-
tively (1).There should be several opportunities to 
further examine the relationship between alcohol use 
and risk of cancer in the available Norwegian cohorts. 
Infectious agents as cause of cancer is not a major prob-
lem in Norway and have not been much examined. 
However, the transition from cytology to primary HPV 
screening programs will provide researchers with data 
related to cervical cancer. 
 
 
REPRODUCTIVE FACTORS AND RISK OF 
CANCER 
 
Already before 1990, epidemiologists created an im-
portant follow-up with interviews of more than 63,000 
women with the objectives to study the associations 
between reproductive factors and cancer (71,72). 
Later, studies based on records from different registers 
including more than 1 million women, have revealed 
new results and confirmed previous knowledge for the 
associations between reproductive factors and breast 
cancer, as well as cancer deaths (73-75). One register-
based study included all Norwegian women born in the 
period 1925 to 1979, i.e. 1.7 million. The results based 
on close to 23,000 incident breast cancer cases, sup-
ported earlier findings that reproductive factors like 
parity, age at birth, and time since birth affect the risk 
of breast cancer. It also found that this differed by 
histological subtypes (76). 
RECORD LINKAGE STUDIES 
 
Researchers in Norway have unique opportunities to 
conduct record linkage studies. This possibility is often 
mentioned as a great advantage in discussions regarding 
Norwegian cancer research. We have already referred 
to some of them. However, the building of huge 
cohorts throughout the world has reduced the scientific 
importance of register-linkage studies. The main rea-
son is the lack of adequate control for the increasing 
number of known confounders. In the future, we 
predict that these analyses will not be included in 
systematic reviews due to this short coming. 
 
 
POPULATION ATTRIBUTABLE FRACTION (PAF) 
 
From a public health point of view, population attri-
butable fraction (PAF) may be as important as the rela-
tive risk measure. This is because PAF more clearly 
express the potential for preventive endeavors. One 
example is that the burden of smoking related cancer 
and deaths from cancer may well be higher than 
previously anticipated (42). Results from NOWAC 
suggest that as many as one in four cancer deaths 
among middle-aged women could have been avoided 
if women in Norway did not smoke (77). Another 
study from NOWAC indicates that the PAF of breast 
cancer due to current use of menopausal hormones is 
as high as 27% (78). The underlying assumptions for 
PAF estimations are a causal relationship combined 
with calculations of PAF values with relative risk es-
timates from the same population. We will encourage 
young researchers to perform PAF analyses, whenever 
it is appropriate, so we increase our knowledge of 
opportunities for cancer prevention. 
 
 
VISIONS FOR THE FUTURE 
 
The ultimate goal is to understand cancer, combat the 
disease and bring it under control. Today we know that 
we cannot treat our way out of the cancer problem. 
Cancer epidemiology is the first step to understand the 
risk factors and causes of cancer and thereby the 
possibility for prevention. One important goal with this 
chapter has been to show the reader some of the 
contributions made by Norwegian researchers in 
cancer epidemiology. We also wanted to show how re-
search in cancer epidemiology has moved from being 
“a one person operation”, to research groups, national 
and international collaborations. A third important 
goal has been to give a short overview of the many 
possibilities for young researchers to get involved, 
utilize the abundance of data available and thereby 
increase our knowledge of the risk factors and causes 
of cancer. The ultimate goal is that this information 
will be used for preventive measures and thereby 
decrease the toll that cancer takes on the Norwegian as 
well as the global population. Today, there are many 
opportunities for young researchers in cancer epidemi-
ology in Norway to make a difference! 
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